SELLAS reports 78 events in REGAL AML trial; Q1 net loss $8.4M, cash $107.1M

SELLAS Life Sciences Group, Inc.

78 events (deaths) occurred in pivotal Phase 3 REGAL trial of GPS in AML as of May 11; final analysis triggered at 80th event.
Cash and cash equivalents $107.1M at March 31, 2026; additional $7.5M from warrant exercises received in Q2 2026.
Net loss $8.4M for Q1 2026 ($0.05 per share) vs $5.8M loss ($0.07 per share) in Q1 2025.
Phase 2 trial of SLS009 in first-line AML dosing patients; topline data expected in Q4 2026.
R&D expenses $5.1M (up from $3.2M); G&A $4.1M (up from $2.9M) driven by BLA preparation and professional fees.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.